• Inhibikase Therapeutics Inc IKT.OQ reported a quarterly adjusted loss of 65 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of two analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -68 cents to -6 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Inhibikase Therapeutics Inc's reported EPS for the quarter was a loss of 65 cents​.

• The company reported a quarterly loss of $5.78 million.

• Inhibikase Therapeutics Inc shares had risen by 86.2% this quarter and gained 90.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 49% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Inhibikase Therapeutics Inc is 6.50

This summary was machine generated from LSEG data November 14 at 08:57 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)